US EditionGLORY-1 outcomes shows positive results for mazdutide - a dual glucagon GCG-1/GLP-1 receptor agonist
Summary by bariatricnews.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
GLORY-1 outcomes shows positive results for mazdutide - a dual glucagon GCG-1/GLP-1 receptor agonist
The results from GLORY-1 - a Phase 3 clinical study of mazdutide - a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity, have revealed the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively.China has the world's largest population of ind…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
